Cephalon exercises option to acquire Ception
24 February 2010
Simon Varcoe
Please Login to read the full article.
24 February 2010
Simon Varcoe
simon.varcoe@informa.com
Cephalon is to pay $250 million to acquire the private US firm Ception Therapeutics after its lead compound Cinquil (reslizumab) achieved positive Phase II data in a study in adults with eosinophilic asthma.
Cephalon paid Ception $100 million up front in January last year for an option agreement...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Stockwatch: Investors struggle with United front for FREEDOM
- InSite to raise $22M to advance PhIII pipeline including combo product for lid margin disease
- Investors give XenoPort 5% nudge on SPA deal with US FDA
- Cephalon options Alba's coeliac disease drug larazotide rejected by shire
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
